Repatha HSA/FSA Eligibility and Submission: A Complete 2026 Guide

Is Repatha an HSA- or FSA-Eligible Expense?

Repatha is HSA- and FSA-eligible because it is a prescription medication. The IRS defines eligible medical expenses in Publication 502, which explicitly covers prescription drugs. Evolocumab 140 mg requires a written or electronic prescription under federal law, so it clears that threshold automatically. No additional documentation is needed beyond the pharmacy receipt that shows the drug name, the dispensing date, and the amount paid.

The IRS Rule That Makes Repatha Eligible

Under 26 U.S.C. § 213(d), a medical expense is deductible (and therefore HSA/FSA-payable) when it is incurred for the diagnosis, cure, mitigation, treatment, or prevention of disease. Repatha carries FDA approval for two distinct disease indications: primary hyperlipidemia and established atherosclerotic cardiovascular disease (ASCVD). Both indications meet the IRS definition. FDA approval documentation is available on the agency's drug database.

HSA vs. FSA: Key Timing Differences

HSA funds roll over indefinitely. FSA funds typically expire at the plan year end, though many employers offer a 2.5-month grace period or a $640 carryover (2024 IRS limit). If you are prescribed Repatha late in a calendar year, prioritizing FSA funds first and HSA funds second is generally the better sequence. The IRS FSA guidance confirms carryover limits are adjusted annually.

How to Pay for Repatha with an HSA or FSA

Paying with an HSA or FSA debit card is the simplest path. Swipe the card at the pharmacy just as you would a credit card. The pharmacy system records the transaction as a prescription purchase, which generates an automatic eligibility flag in most HSA/FSA administrator systems.

Paying at the Pharmacy Counter

Most major pharmacy chains (CVS, Walgreens, Rite Aid, specialty mail-order pharmacies) accept HSA and FSA debit cards on the Visa or Mastercard network. Repatha is typically dispensed through a specialty pharmacy rather than a retail chain, because it requires cold-chain storage. Confirm that your specialty pharmacy of record accepts HSA/FSA debit before your first fill.

Submitting a Reimbursement Claim

If you paid out of pocket first, you can request reimbursement from your HSA or FSA administrator:

1. Obtain an itemized receipt from the specialty pharmacy showing the drug name, NDC number, dispensing date, and amount paid.
2. Log in to your HSA/FSA plan portal and submit a reimbursement claim.
3. Attach the itemized receipt as the substantiation document.
4. Most administrators process claims within 3 to 10 business days.

The IRS requires substantiation for FSA claims. HSA withdrawals are self-reported on Form 8889 at tax time; keep all receipts for at least three years in case of audit.

What Documentation to Keep

Keep the pharmacy receipt, the explanation of benefits (EOB) from your insurer if insurance paid first, and any copay card transaction records. The combination of these three documents fully substantiates the expense if your HSA custodian or the IRS questions the claim.

Stacking HSA/FSA with the Amgen Repatha Copay Card

The Amgen copay assistance program for Repatha is one of the most aggressive manufacturer programs available for a branded injectable. Commercially insured patients may pay as little as $0 per month. Patients without insurance may access a separate patient assistance pathway.

How the Copay Card Works

Amgen's program reduces the amount you owe at the pharmacy to a target of $0 for eligible commercially insured patients. Your insurer pays its portion first. Amgen's copay card covers most or all of the remaining balance. If any residual balance exists after the copay card is applied, that residual amount is what you would pay from your HSA or FSA.

The practical stacking sequence is:

1. Insurance adjudicates the claim and pays its contracted rate.
2. Amgen copay card applies to reduce the patient copay or coinsurance.
3. Any remaining balance is paid with an HSA or FSA debit card.
4. Submit an itemized receipt to your HSA/FSA administrator for the amount actually paid in step 3.

This sequence is confirmed as permissible under current IRS guidance for commercially insured individuals. Medicare and Medicaid beneficiaries cannot use manufacturer copay cards (federal anti-kickback statute prohibits this), but they may still use HSA or FSA funds if they have a qualifying high-deductible health plan (HDHP) with an HSA or a general-purpose FSA through an employer.

Copay Card and HSA Eligibility: The Medicare Exception

Patients enrolled in Medicare Part D cannot use the Amgen copay card, and Medicare beneficiaries generally cannot contribute to an HSA. However, funds already accumulated in an HSA before Medicare enrollment can still be used to pay Repatha costs. This is confirmed by IRS Publication 969, which states that existing HSA balances remain available for qualified medical expenses even after you enroll in Medicare.

Why Repatha Is Prescribed: Clinical Context

Understanding the clinical rationale helps you document the medical necessity of the expense, which can be relevant when submitting claims or appealing insurance denials.

The FOURIER Trial

The key FOURIER trial (N=27,564) tested evolocumab 140 mg every 2 weeks (or 420 mg monthly) versus placebo in patients with established ASCVD already on statin therapy. After a median follow-up of 26 months, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% in relative terms (9.8% vs. 11.3%, HR 0.85; P<0.001). Sabatine et al. Published the full results in the New England Journal of Medicine.

LDL-C fell by a mean of 59% from baseline in the evolocumab group, reaching a median on-treatment LDL-C of 30 mg/dL. The NEJM publication remains the primary evidence source for the ASCVD indication.

The GLAGOV Intravascular Ultrasound Trial

GLAGOV (N=968) demonstrated that evolocumab, added to statin therapy, produced regression of coronary atherosclerosis over 76 weeks as measured by intravascular ultrasound. Percent atheroma volume decreased by 0.95% in the evolocumab group versus an increase of 0.05% in the placebo group (P<0.001). Nicholls et al. Reported these findings in JAMA. This trial strengthens the biological rationale for long-term therapy, which in turn supports the ongoing HSA/FSA expense.

ACC/AHA Guideline Support

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends PCSK9 inhibitor therapy for very-high-risk ASCVD patients whose LDL-C remains above 70 mg/dL despite maximally tolerated statin therapy. The guideline states: "For patients with clinical ASCVD who are at very high risk and in whom LDL-C remains ≥70 mg/dL, it is reasonable to add a PCSK9 inhibitor." The full guideline is published in the Journal of the American College of Cardiology. This recommendation provides clear documentation of medical necessity for insurance appeals and HSA/FSA substantiation.

The American Heart Association's cholesterol management guidance mirrors this recommendation, noting that PCSK9 inhibitors offer the largest LDL-C reductions available for patients who cannot achieve target levels on statins alone.

How to Get Repatha Cheaper: All Cost-Reduction Strategies

Several mechanisms can reduce out-of-pocket Repatha costs beyond HSA/FSA spending alone.

Amgen Patient Assistance Program (Repatha SupportPlus)

Amgen's SupportPlus program covers commercially insured and uninsured patients. Eligibility is income-based for the uninsured pathway. The program can be accessed through the prescribing physician's office or directly at Amgen's patient support line. Enrollment typically requires proof of insurance status, household income documentation, and a prescription from a licensed prescriber.

The FDA approval of evolocumab is under BLA 125522. The FDA label outlines approved doses: 140 mg every 2 weeks subcutaneously, or 420 mg once monthly via the Pushtronex on-body infusor system.

Step Therapy and Prior Authorization

Most commercial and Medicare Advantage plans require step therapy before approving evolocumab. A typical sequence is:

• Maximum tolerated statin for at least 90 days.
• Addition of ezetimibe for at least 90 days if LDL-C remains above goal.
• Documentation of LDL-C still above 70 mg/dL (or 55 mg/dL for very-high-risk patients per ESC/EAS guidelines).

Completing step therapy and documenting it in the chart speeds prior authorization approval and reduces the chance of a claim denial that would require out-of-pocket payment. The ACC/AHA guidelines provide the LDL-C threshold evidence that supports these criteria.

Specialty Pharmacy Mail-Order Discounts

Repatha requires refrigeration (2°C to 8°C). Some specialty pharmacies offer 90-day supply dispensing at a reduced per-unit cost compared to a monthly supply. Verify with your plan whether a 90-day supply is covered before requesting it. Using your HSA/FSA for a 90-day supply at once can also simplify year-end FSA spend-down.

Biosimilar Field in 2026

As of early 2026, the first evolocumab biosimilar has entered the regulatory pipeline in the United States. The FDA's biosimilar approval pathway under 351(k) means that once an interchangeable biosimilar is approved, pharmacists may substitute it without prescriber intervention in most states. An interchangeable biosimilar would be fully HSA/FSA eligible by the same IRS logic, because it is still a prescription drug treating the same indication. FDA biosimilar approval records are updated as new products receive approval.

Special Populations and HSA/FSA Nuances

Patients with Familial Hypercholesterolemia

Heterozygous familial hypercholesterolemia (HeFH) affects approximately 1 in 250 people in the United States, and homozygous FH (HoFH) affects approximately 1 in 300,000. A 2019 analysis in the Journal of Clinical Lipidology confirmed that PCSK9 inhibitors produce substantially greater absolute LDL-C reductions in FH patients than in non-FH patients because baseline LDL-C is higher. For HeFH patients, evolocumab 140 mg every 2 weeks reduced LDL-C by a mean of 60% in the RUTHERFORD-2 trial (N=329), as reported in The Lancet. These patients often face the highest absolute drug costs and benefit most from stacking HSA, FSA, and manufacturer assistance.

Patients Using a Limited-Purpose FSA

Some HDHP enrollees have a limited-purpose FSA (LP-FSA), which restricts eligible expenses to dental and vision only until the HDHP deductible is met. Repatha expenses do not qualify under an LP-FSA until the deductible threshold is satisfied. Once the deductible is met, the LP-FSA becomes a general-purpose FSA and Repatha claims are eligible. Confirm your LP-FSA terms with your plan administrator.

Dependent Care FSA

A dependent care FSA covers childcare expenses, not medical expenses. It cannot be used for Repatha under any circumstance. This is a common point of confusion when employers offer multiple FSA account types simultaneously.

Repatha Safety and Monitoring: What Your Prescriber Will Track

The FDA label requires no routine laboratory monitoring specific to evolocumab itself. Prescribers typically check a fasting lipid panel 4 to 12 weeks after initiating therapy to confirm LDL-C response, consistent with ACC/AHA guideline recommendations. Liver function tests and creatine kinase are not required on the label, unlike with statin initiation.

Injection-site reactions occurred in 2.1% of FOURIER participants. Nasopharyngitis was the most common adverse event (approximately 8.7% vs. 8.0% placebo). The FDA prescribing information notes no clinically meaningful increase in diabetes risk, distinguishing evolocumab from high-intensity statins, which carry a small but documented diabetes risk per a 2010 meta-analysis in The Lancet.

The EBBINGHAUS cognitive substudy of FOURIER (N=1,974) found no significant difference in neurocognitive function between evolocumab and placebo despite achieving very low LDL-C levels. Results were published in the New England Journal of Medicine. This finding addressed earlier theoretical concerns about extremely low LDL-C and cognitive safety.

Practical Checklist Before Your First HSA/FSA Repatha Claim

• Confirm your HSA or FSA plan accepts specialty pharmacy receipts as substantiation.
• Ask the specialty pharmacy for an itemized receipt with the NDC number at every fill.
• Enroll in the Amgen SupportPlus copay program before the first fill to reduce the balance you need to pay from your account.
• Set a calendar reminder 60 days before your FSA plan year ends to assess remaining balance and schedule refills accordingly.
• If your insurer denies prior authorization, request a peer-to-peer review between your cardiologist or lipidologist and the insurer's medical director, citing FOURIER and the ACC/AHA cholesterol guideline.
• Keep all receipts and EOBs for a minimum of three years as required by IRS HSA audit guidance.